Abstract:Rosiglitazone is a peroxisome proliferator activated receptor-γ(PPAR-γ) agonist available to improve glucose metabolism in patients with Type 2 diabetes. Recent evidence suggests that therapeutic use of rosiglitazone have caused unwanted hematological side effects, such as anemia, leukopenia, thrombocytopenia, even pancytopenia. However, others reported that pretreatment with rosiglitazone for 5 days could protect against 5-Fu-induced myelotoxity which is FLT3 dependent. Thus, it is still unclear the exact effects of rosiglitazone treatment on homeostatic and stress hematopoiesis. Rosiglitazone is a potent stimulator of adipogenesis, as it can induce adipogenic differentiation both in vitro and in vivo. Recently, it was reported that adipocyte-rich bone marrow(BM) harbored a decreased frequency of progenitor cells. Furthermore, our laboratory and those of other investigators have demonstrated that BADGE, an inhibitor of PPAR-γ signaling pathway, can improved the hematopoietic recovery in response to stress. So we hypothesize that long-term treatment of rosiglitazone may inhibit the hematopoiesis by inducing BM adipogenesis. In this study, we first treated C57BL/6J mice with 37.5mg/kg rosiglitazone for six weeks to examine the long-term effect of rosiglitazone on hematopoiesis in vivo. We found that rosiglitazone treatment does not alter body weight or BM function of normal healthy mice. In response to 5-Fu induced hematopoietic stress, rosiglitazone group mice exhibited delayed recovery of WBC and BMMNC. Furthermore, the frequency and absolute number of GMP and CLP cells in rosiglitazone group was decreased at d14 after 5-Fu. Concomitantly, we found that CFU-GM counts of rosiglitazone group BM were significantly decreased when compared with control group mice, while CFU-GEMM counts revealed no difference. However, we didn9t observed any alteration in absolute number of LSK cells between the two groups, although rosiglitazone group mice had increased percentage of LSK. These results indicated that rosiglitazone could maintain the HSC compartment while impair myeloid differentiation from myelosuppressive stress, which may explain the delayed hematopoietic recovery in rosiglitazone group. To answer the question whether the effects of rosiglitazone were directly mediated, in vitro cultures were used. We cultured d3 5-Fu BM cells (BM cells harvested 3 day after 5-FU administration) in the presence of rosiglitazone to detect whether rosiglitazone inhibited hematopoietic progenitor cells in stress condition. Cell proliferation of Lin- cell was unaffected at pharmacologically achievable concentrations of rosiglitazone. However, rosiglitazone at high concentrations (u003e10μM) significantly inhibit cell proliferation of Lin- cell, which was in agreement with previous reports. To confirm our results, we choose two other TZD drugs to test whether cell proliferation was affected. Similarly, neither troglitazone nor pioglitazone exhibited an inhibition effect on cell proliferation at pharmacologically achievable concentrations. Furthermore, rosiglitazone treatment didn9t decrease the numbers of CFU-GM. These data show that rosiglitazone can not directly inhibit cell proliferation or myeloid differentiation of HPC in stress condition. As long-term treatment of rosiglitazone caused a significant increase of BM adipocytes in mice, we speculated that impaired myeloid differentiation in rosiglitazone group mice may be due to enhanced adipogenesis. We found that rosiglitazone promoted the adipogenic differentiation of two stromal cell lines (C3H10T1/2,M2-10B4). In addition, rosiglitazone treated stromal cell lines significantly inhibited cell proliferation and myeloid differentiation of co-cultured Lin- cells. In conclusion, rosiglitazone induced BM adipogenesis can impair the myeloid differentiation of hematopoietic stem cell, which may contribute to a significant delay in hematopoietic recovery after chemotherapeutic stress. Further investigation of the molecular mechanism is warranted and may enable the development of therapies effective for suppressed hematopoiesis induced by TZDs. Disclosures No relevant conflicts of interest to declare.

Rosiglitazone Exerts an Anti-depressive Effect in Unpredictable Chronic Mild-Stress-Induced Depressive Mice by Maintaining Essential Neuron Autophagy and Inhibiting Excessive Astrocytic Apoptosis

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosiglitazone Mitigates Dexamethasone-Induced Depression in Mice via Modulating Brain Glucose Metabolism and AMPK/mTOR Signaling Pathway

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

PI3K/AKT/JNK/p38 Signalling Pathway-Mediated Neural Apoptosis in the Prefrontal Cortex of Mice is Involved in the Antidepressant-Like Effect of Pioglitazone

Glucagon-like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-like Behaviors in Diabetic Mice

Rosiglitazone Promotes White Matter Integrity And Long-Term Functional Recovery After Focal Cerebral Ischemia

Mir-16 and Fluoxetine Both Reverse Autophagic and Apoptotic Change in Chronic Unpredictable Mild Stress Model Rats.

Activating PPARβ/δ Protects against Endoplasmic Reticulum Stress-Induced Astrocytic Apoptosis via UCP2-Dependent Mitophagy in Depressive Model

Age-related Dysfunction of Insulin Degrading Enzyme (IDE) and Insulin Signaling Pathway and the Reversive Effect of Rosiglitazone

Rosiglitazone Ameliorates Senescence-Like Phenotypes in a Cellular Photoaging Model.

FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats

Ginsenoside Rg1 Reduced Microglial Activation and Mitochondrial Dysfunction to Alleviate Depression-Like Behaviour Via the GAS5/EZH2/SOCS3/NRF2 Axis

Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists

Rosiglitazone Promotes Atherosclerotic Plaque Stability In Fat-Fed Apoe-Knockout Mice

Long-Term Treatment With Rosiglitazone Delays Hematopoietic Recovery In Response To Stress

Ginsenoside Rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis

Cell proliferation and neuroblast differentiation in the dentate gyrus of high-fat diet-fed mice are increased after rosiglitazone treatment

Inhibition of Glycolysis Alleviates Chronic Unpredictable Mild Stress-Induced Neuroinflammation and Depression-like Behavior

NLRP3 inflammasome-dependent pyroptosis and apoptosis in hippocampus neurons mediates depressive-like behavior in diabetic mice